Document is current
Any future updates will be listed below
-
Authors
Davis-Porada, Julia
Tozlu, Ceren
Aiello, Claudia
Apostolidis, Sokratis A.
Bar-Or, Amit
Bove, Riley
Espinoza, Diego A.
Ferreira Brito, Sugeidy
Jacobs, Dina
Kakara, Mihir
Onomichi, Kaho
Ricci, Adelle
Sabatino, Joseph J. Jr.
Walker, Elizabeth
Wherry, E. John
Zhang, Lili
Zhu, Wen
Xia, Zongqi
De Jager, Philip
Wesley, Sarah Flanagan
Straus Farber, Rebecca
Farber, Donna L.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (F30AI74785, U19AI128949, U19AI128949, U19AI128949)
National Multiple Sclerosis Society (TA-2204-39428)
Novartis Pharmaceuticals Corporation (COMB157GUS20T, COMB157GUS20T)
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 30 April 2025
First Online: 17 May 2025
Competing interests
: A.B.-O. receives research funding NIH, The National MS Society (NMSS), the Juvenile Diabetes Research Foundation (JDRF), the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation and Melissa and Paul Anderson Chair in Neuroinflammation, and has received grant support to the University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis; has Received personal fees for advisory board participation and/or consulting from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme. R.B. is the recipient of a National Multiple Sclerosis Harry Weaver Award, and has received research support from the National Multiple Sclerosis Society, the National Institutes of Health and the Department of Defense; has received research support from Biogen, Eli Lilly, Novartis and Roche Genentech; has received personal compensation for consulting from Alexion, Amgen, EMD Serono, Sanofi Genzyme, and TG Therapeutics. D.J. has received personal compensation for advisory boards and consulting for Alexion, Horizon, Roche/Genentech, Biogen, Merck/EMD Serono, TG Therapeutics and has received grant support to the University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis. J.S. has research funding support from Novartis and Roche-Genentech. Z.X. has served as a Consultant for Genentech/Roche, and the institution of Xia has received research support from NIH, the Pittsburgh Foundation and Genentech /Roche. P.D.J. has consulted for Puretech, Biogen, Novo Nordisk and has research sponsored by Roche, Puretech, and Biogen. S.F.W. has consulted for Novartis, TG Therapetuics, Genetech and has received research support from the NIH and investigator-initiated research funding from Biogen and Novartis. R.S.F. has consulted for Alexion, Roche/Genentech, Horizon Therapeutics, and has investigator-initiated research funded by Novartis and Biogen. All other authors declare no financial or non-financial competing interests.
